Infectious Diseases & Vaccines
COVID may have been unprecedented, but our vaccine experience, sit solutions, systems, process, tools and support meant we were ready, and will continue to be.
Our advanced analytics includes real-time simulation of active cases, near real time surveillance and impact analysis. Plus, expertise in influenza and COVID-19, clinical trial acceleration and advance response time and vaccine development.
We have diverse teams with experience in over 400 trials in more than 90 countries, excluding COVID-19 trials, in the last 10 years.
Our expertise covers drug and interventional vaccine development, immunization for high-risk groups, and severe RSV case management including infants and adults; additional experience in respiratory health.
With cutting-edge diagnostic testing, global expertise and advanced technologies, and decades of experience, our solutions ensure high-quality infrastructure and precise HBV testing, driving impactful results and healthcare advancements.
Our extensive experience includes collaboration with local authorities, supporting development of strong laboratory networks and services, has revolutionized treatment, saving lives and transforming public health outcomes.
With our integration of advanced analytics, real-world evidence and technology, we support life-changing therapies and enhance global HIV care. Combined with our decades of experience, we drive innovative solutions, improving patient outcomes.
IQVIA continues to work with partners around the world in supporting Community Health Workers with improved training, education, and support services for better public health. Read more here.
It is an increasingly diverse and dynamic environment with new and re-emerging pathogens. The study of infectious diseases and vaccines is as complex as the populations and environments they impact. Timing of treatment and protection is critical for seasonal preparedness or pandemic relief.
Our global IQVIA specialized team of scientific, medical, and operational experts can design and deliver complex clinical
trials by
IQVIA supports sponsors of every size and at every stage, including government and nonprofit organizations, to advance broader public health goals. IQVIA is a Global Health Clinical Consortium partner and has conducted BARDA, NIH, and CEPI funded trials. We have delivered trials in disease areas from influenza, anthrax, and Ebola to acute radiation syndrome and nerve agent countermeasures. We understand clinical development challenges and offer strategies and solutions to address your specific and unique trial needs.
Navigating the nuances of infectious diseases requires having the right resources at the right time in order to meet critical timelines. A partner with global presence and proven record is a must. IQVIA integrates unparalleled data and transformative technology, making intelligent connections to help you.
Use big data and predictive analytics to improve human health.
Our latest thinking on infectious disease and vaccines
Solutions you may be interested in
Big data coupled with predictive analytics can help your agency or organization at every level – from national to local. IQVIA is positioned to help you turn the world’s largest source of curated information into actionable insights.
Access central labs around the globe through IQVIA Laboratories, a wholly owned subsidiary of IQVIA.
Leverage a global network of Phase I clinical pharmacology units to build diversity in patient populations and access a range of geographic regions for early clinical development (ECD) programs.
Improve the performance of your clinical trials with the power of the IQVIA CORE™.
Access new resources for advanced therapy development, from candidate identification through market authorization.
From concept to market, we can meet your ever-increasing needs in regulatory, safety and compliance
.svg){kind=icon}
